scholarly journals Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Masashi Shimoda ◽  
Maiko Miyoshi-Takai ◽  
Shintaro Irie ◽  
Akihito Tanabe ◽  
Atsushi Obata ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Dipeptidyl Peptidase ◽  
Hypoglycemic Agents ◽  
Baseline Hba1c ◽  
Glucose Lowering ◽  
Dipeptidyl Peptidase 4 ◽  
Lowering Effect ◽  
Glucose Lowering Effect ◽  
Effective Group

Dipeptidyl peptidase-4 (DPP-4) inhibitors are often used all over the world and exert various beneficial effects including glucose-lowering effect in many subjects with type 2 diabetes. It is poorly understood, however, which factors are closely related with the durability of glucose-lowering effect by DPP-4 inhibitor. In this study, we examined retrospectively which factors could mainly influence the durability of DPP-4 inhibitor. We enrolled 212 participants with type 2 diabetes to whom DPP-4 inhibitor was administered for over 1 year without an addition or increase of other hypoglycemic agents. Age and baseline HbA1c level were significantly higher in the effective group than those in the ineffective group. The effective group had a tendency of smaller amounts of weight change, average total cholesterol, and average triglyceride compared with the ineffective group. Multiple logistic regression analysis showed that average triglyceride and baseline HbA1c were independent predictors associated with the durability of DPP-4 inhibitor. Moreover, an average triglyceride level contributed to the durability of DPP-4 inhibitor in the obese group (BMI ≥ 25 kg/m2) but not in the nonobese group (BMI < 25 kg/m2). These results suggest the importance of strict triglyceride management to maintain the durability of glucose-lowering effect by DPP-4 inhibitor, especially in obese subjects with type 2 diabetes.

scholarly journals Efficacy of switching from dipeptidyl peptidase-4 inhibitors to dulaglutide in patients with type 2 diabetes

2019 ◽  
Author(s):  
Koki Chiba ◽  
Mayuko Oita ◽  
Hiroyuki Nakamura ◽  
Ayano Utsunomiya ◽  
Yui Kosumi ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Plasma Glucose ◽  
Dipeptidyl Peptidase ◽  
City Hospital ◽  
Baseline Hba1c ◽  
Dipeptidyl Peptidase 4 ◽  
Receptor Agonists ◽  
Dipeptidyl Peptidase 4 Inhibitors

Abstract Background: Several reports showed that the effects of daily Glucagon-like peptidase-1 (GLP-1) receptor agonists for lowering plasma glucose and body weight are superior to those of dipeptidyl peptidase-4 (DPP-4) inhibitors, while the superiority of weekly GLP-1 receptor agonists, dulaglutide, is still unclear. The aim of this study was to evaluate the efficacy of dulaglutide therapy switching from DPP-4 inhibitors in patients with type 2 diabetes. Methods: We retrospectively evaluated the 79 Japanese patients with type 2 diabetes at the Diabetes Outpatient Clinic in Tomakomai City Hospital whose treatment was switched from DPP-4 inhibitors to dulaglutide. We investigated the change of hemoglobin A1c (HbA1c), casual plasma glucose (CPG) levels and body weight 4 weeks, 8 weeks and 12 weeks after switching from DPP-4 inhibitors to dulaglutide. In addition, we defined the group in which HbA1c was improved more than 1% as “improved group” (n = 37) and the group in which HbA1c was improved less than 1% as “non-improved group” (n = 42), and compared the patients’ background in both the groups. The subtraction of HbA1c at each weeks and baseline HbA1c was defined as ⊿HbA1c. Results: After switching to dulaglutide, HbA1c showed a significant decrease from 4 weeks later, and the effect was maintained even after 12 weeks. The “improved group” had lower estimated glomerular filtration rate (eGFR) and higher baseline HbA1c than the “non-improved group”. In the “improved group”, ⊿HbA1c showed a significant correlation with eGFR and baseline HbA1c. Conclusion: Switching from DPP-4 inhibitors to dulaglutide could improve HbA1c, especially in cases with low eGFR and high HbA1c.

scholarly journals Fast‐acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose‐lowering effect compared with insulin aspart

2019 ◽  
Vol 21 (9) ◽  
pp. 2068-2075 ◽  
Author(s):  
Thomas R. Pieber ◽  
Eva Svehlikova ◽  
Martina Brunner ◽  
Inge B. Halberg ◽  
Karen Margrete Due Thomsen ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Insulin Aspart ◽  
Initial Exposure ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Acting Insulin ◽  
Glucose Lowering Effect ◽  
Fast Acting

Prior meal enhances the plasma glucose lowering effect of exercise in type 2 diabetes

2001 ◽  
Vol 33 (8) ◽  
pp. 1259-1264 ◽  
Author(s):  
PAUL POIRIER ◽  
SAMANTHA MAWHINNEY ◽  
LUC GRONDIN ◽  
ANGELO TREMBLAY ◽  
TOM BRODERICK ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasma Glucose ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect

scholarly journals Glucose-Lowering Effect of Home-Delivered Therapeutic Meals in Patients with Type 2 Diabetes

2020 ◽  
Vol 21 (1) ◽  
pp. 46-54
Author(s):  
Jong Han Choi ◽  
Se Hee Min ◽  
Kyeong Hye Lim ◽  
Uoon Jeong Shin ◽  
Min-Seon Kim
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Lowering ◽  
Lowering Effect ◽  
Glucose Lowering Effect
Sign in / Sign up

Export Citation Format

Share Document